Compare FET & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FET | SLDB |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.7M | 498.6M |
| IPO Year | 2007 | 2017 |
| Metric | FET | SLDB |
|---|---|---|
| Price | $57.86 | $5.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $14.70 |
| AVG Volume (30 Days) | 235.9K | ★ 1.2M |
| Earning Date | 05-23-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $816,425,000.00 | $8,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.50 | N/A |
| 52 Week Low | $12.78 | $2.45 |
| 52 Week High | $53.50 | $7.37 |
| Indicator | FET | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 78.33 | 42.89 |
| Support Level | $50.99 | $5.23 |
| Resistance Level | $49.13 | $6.18 |
| Average True Range (ATR) | 2.30 | 0.53 |
| MACD | 0.41 | -0.13 |
| Stochastic Oscillator | 87.17 | 20.48 |
Forum Energy Technologies Inc is a products company, serving the oil, natural gas, industrial and renewable energy industries. The company designs, manufactures, and distributes products and engages in aftermarket parts supply and services that complement its product offering. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. It operates in two reporting segments, namely Drilling and Completions and Artificial Lift and Downhole. Revenue largely comes from Artificial Lift and Downhole segment.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.